SCHEMBL22708729

SCHEMBL22708729

c1ccc(-c2ccc3sc4c5[nH]c6ccccc6c5c5ccccc5c4c3c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MAP3K9 P80192 3/20 0.49
▸ MAP3K11 Q16584 3/20 0.49
▸ CDK4 P11802 3/20 0.49
▸ CCND1 P24385 3/20 0.49
▸ TNKS O95271 2/20 0.47
▸ TNKS2 Q9H2K2 2/20 0.47
▸ HTT P42858 3/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ PPARG P37231 1/20 0.46
▸ NCOA2 Q15596 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ NTRK1 P04629 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15139068 0.95 MEN1 (0.48) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL14951565 0.92 MEN1 (0.51) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL14951582 0.92 MEN1 (0.51) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL22133226 0.89 MAP3K9 (0.49) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL18132843 0.89 MEN1 (0.51) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL18346740 0.89 MAPT (0.46) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL24519165 0.86 MAP3K9 (0.49) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL14951579 0.86 MEN1 (0.48) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL15003805 0.86 MEN1 (0.48) MEN1KMT2AMAPTRAB9AMAP3K9
SCHEMBL14951581 0.86 MEN1 (0.48) MEN1KMT2AMAPTRAB9AMAP3K9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11588110-B2 Heterocyclic compound and organic light emitting device comprising the same LT MATERIALS CO., LTD. (KR) 2023-02-21 — — US disclosed
US-20200373499-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LT MATERIALS CO., LTD. (KR) 2020-11-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11588110-B2 Heterocyclic compound and organic light emitting device comprising the same CRY1, CYP1A1, CYP1B1 MEN1 279/4885KMT2A 887/4885MAPT 1801/4885
US-20200373499-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CYP1A1, CYP1B1 MEN1 279/4885KMT2A 887/4885MAPT 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback